Alternative splicing attenuates transgenic expression directed by the apolipoprotein E promoter-enhancer based...

Area of Science:

• Molecular Biology
• Genetics
• Biotechnology

Background:

• The pLIV11 plasmid vector is widely used for liver-specific gene expression in transgenic animals.
• Expression is regulated by the human apolipoprotein (apo)E promoter and a hepatic control region.
• Inserted cDNA sequences can lead to unintended exon 2 skipping due to cryptic splice sites.

Purpose of the Study:

• To investigate the mechanism of exon 2 skipping in the pLIV11 vector.
• To develop a strategy to prevent alternative splicing and ensure accurate gene expression.

Main Methods:

• Modification of the pLIV11 vector by inserting an engineered 3' splice acceptor site.
• Analysis of splicing patterns in transgenic animals carrying the modified vector.

Main Results:

• Inserted cDNA sequences in the pLIV11 vector's multiple cloning site (MCS) can cause exon 2 skipping.
• The engineered splice acceptor site effectively redirected splicing, preventing exon 2 skipping.
• This modification protected cloned sequences from alternative splicing and potential expression attenuation.

Conclusions:

• Sequences inserted into the pLIV11 vector's MCS can influence exon 2 recognition and splicing.
• An engineered splice acceptor site provides a robust strategy to prevent alternative splicing events.
• This modification enhances the reliability of the pLIV11 vector for transgenic expression studies.